Financial Performance - Net loss for the three months ended September 30, 2021, was $7,989,000, compared to a net loss of $4,716,000 for the same period in 2020, indicating an increase in loss of approximately 69%[21] - Comprehensive loss for the nine months ended September 30, 2021, was $27,136,000, compared to $18,382,000 for the same period in 2020, representing an increase of approximately 47%[24] - The net loss for the nine months ended September 30, 2021, was $27.146 million, compared to a net loss of $18.379 million for the same period in 2020[33] - The company reported a net loss of $8.0 million for the three months ended September 30, 2021, compared to a net loss of $4.7 million for the same period in 2020, representing a 70% increase in losses[74] - The company incurred a net loss of $8.0 million for Q3 2021, compared to $4.7 million for Q3 2020, and a total net loss of $27.1 million for the nine months ended September 30, 2021, compared to $18.4 million for the same period in 2020[149] Assets and Liabilities - Total current assets decreased to $74,496,000 as of September 30, 2021, down from $99,240,000 as of December 31, 2020, representing a decline of approximately 25%[19] - Total liabilities decreased to $4,502,000 as of September 30, 2021, down from $7,008,000 as of December 31, 2020, a reduction of about 36%[19] - Cash and cash equivalents decreased to $11,452,000 as of September 30, 2021, down from $33,418,000 as of December 31, 2020, a decline of about 66%[19] - The accumulated deficit increased to $(160,513,000) as of September 30, 2021, compared to $(133,367,000) as of December 31, 2020, reflecting an increase in deficit of approximately 20%[19] - As of September 30, 2021, the accumulated deficit was $160.5 million, with cash, cash equivalents, and short-term investments totaling $72.6 million[74] Operating Expenses - Total operating expenses for the three months ended September 30, 2021, were $8,017,000, up from $6,821,000 in the same period of 2020, reflecting an increase of about 17.5%[21] - General and administrative expenses surged to $4.0 million for the three months ended September 30, 2021, a 94% increase from $2.1 million in 2020, driven by higher stock-based compensation and insurance costs[99] - For the nine months ended September 30, 2021, total operating expenses were $27.2 million, a 32% increase from $20.7 million in 2020[102] - General and administrative expenses for the nine months ended September 30, 2021, reached $12.6 million, up from $5.2 million in 2020, primarily due to increased stock-based compensation and insurance costs[106] Research and Development - Research and development expenses for the nine months ended September 30, 2021, were $14,635,000, compared to $15,474,000 for the same period in 2020, showing a decrease of approximately 5.4%[21] - Research and development expenses decreased to $4.0 million for the three months ended September 30, 2021, down 15% from $4.8 million in 2020, mainly due to reduced clinical trial expenses[96] - The company expects to continue incurring significant and increasing operating losses for the foreseeable future due to ongoing research and development activities[150] - The company anticipates substantial increases in expenses related to clinical trials, regulatory approvals, and commercialization efforts for its product candidates[155] Funding and Capital Needs - The company plans to seek additional funding to advance its research and development programs and meet its obligations[39] - The company expects to finance its future cash needs through equity offerings, debt financings, or other capital sources, as it anticipates continued losses until substantial product revenue is generated[111] - The company has no credit facility or committed sources of capital, indicating a potential need for additional funds to meet operational needs[116] - The company may need to raise additional capital to support its operations and growth strategy, and failure to do so could delay or eliminate product development programs[155] Clinical Trials and Product Development - GB-102, the lead product candidate, demonstrated durable clinical evidence of disease control in approximately 88% of patients in a Phase 1/2a clinical trial[72] - The company has stopped further development of GB-103 due to the observed 12-month duration of GB-102 in clinical trials[72] - The Phase 2b clinical trial of GB-102 showed that patients on the 1 mg dose had a mean Best Corrected Visual Acuity (BCVA) approximately 9 letters lower than the control arm receiving Eylea, raising concerns about FDA approval[175] - The company has not yet successfully initiated or completed any Phase 3 clinical trials nor commercialized any pharmaceutical products, making future prospects difficult to evaluate[149] - Clinical trials are inherently uncertain, and positive results in early trials do not guarantee success in later-stage trials[179] Impact of COVID-19 - The ongoing COVID-19 pandemic has not significantly impacted the company's financial condition or operations to date, but future effects remain uncertain[77] - The pandemic has caused delays in clinical trials and may impact the ability to monitor patients due to clinic closures[195] - The company anticipates that disruptions in supply chains could delay the start of clinical trials for product candidates[195] - The pandemic has negatively impacted capital markets, which may affect the company's liquidity and access to capital[196] Cybersecurity and Operational Risks - The majority of office-based employees have been working remotely since March 2020, which has increased cybersecurity risks[193] - Cybersecurity breaches could result in significant business disruptions and damage to the company's reputation[215]
CalciMedica(CALC) - 2021 Q3 - Quarterly Report